Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | Challenges in interpreting the results of genomic tests in CLL

Florence Cymbalista • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, comments on the challenges of interpreting the results of genomic tests in chronic lymphocytic leukemia (CLL), highlighting the need for quality control, particularly with next-generation sequencing (NGS) methods. Prof. Cymbalista also discusses the importance of communicating the results from these tests to patients in an understandable way. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Florence Cymbalista

2:30
Towards strategies to optimize outcomes in CLL
Florence Cymbalista • 7 Oct 2022
2:07
Moving towards time-limited treatment in frontline CLL
Florence Cymbalista • 7 Oct 2022
2:27
The importance of TP53 & IGHV testing before treatment initiation in CLL
Florence Cymbalista • 7 Oct 2022
1:21
Identifying low-burden TP53 mutations with NGS in CLL
Florence Cymbalista • 7 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals